Optimi Health (TSE:OPTI) has released an update.
Optimi Health Corp. has marked a significant milestone by successfully exporting GMP-validated MDMA capsules to Australia, targeting PTSD treatment through the Authorised Prescriber Scheme. Additionally, they have advanced their global footprint by shipping GMP natural psilocybin extract to New Zealand for a pilot study. The company’s influence on the Australian regulatory framework has been recognized, and they have successfully closed the first tranche of a recent private placement, raising CAD$538,999.80.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
